ArticleNanomedicine : nanotechnology, biology, and medicine2012
Tracking T-cells in vivo with a new nano-sized MRI contrast agent.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Mapping Therapeutic Regulatory T Cell Fate with MRI: Current Strategies and Translational Outlook.Nanomaterials (Basel, Switzerland) · 2026Review
- Magnetic Particle Imaging Distinguishes Viable and Damaged Cells by Exploiting Distinct Magnetic Signatures of Internalized Nanoparticles.Small science · 2026Article
- Ultrasound medicine in the era of precision theranostics: Mechanisms, molecular strategies, and clinical translation.Iranian journal of basic medical sciences · 2026Review
- Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging.Journal of translational medicine · 2025Review
- Recent progress of nanomaterials for diagnosis and treatment of rejection in heart transplantation.Frontiers in bioengineering and biotechnology · 2025Review
- Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment.Bioactive materials · 2024Review
- Nanoparticle-based T cell immunoimaging and immunomodulatory for diagnosing and treating transplant rejection.Heliyon · 2024Review
- Recent Advancements in Biomaterials for Chimeric Antigen Receptor T Cell Immunotherapy.Biomaterials research · 2024Review
- High-efficiency magnetophoretic labelling of adoptively-transferred T cells for longitudinalTheranostics · 2024Article
- Theranostic Role of Iron Oxide Nanoparticle for Treating Renal Anemia: Evidence of Efficacy and Significance by MRI, Histology and Biomarkers.Pharmaceutics · 2023Article
- MegaPro, a clinically translatable nanoparticle forTheranostics · 2023Article
- Cell sorting microbeads as novel contrast agent for magnetic resonance imaging.Scientific reports · 2022Article
- Article
- In vivo imaging of nanoparticle-labeled CAR T cells.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Nanodrugs Targeting T Cells in Tumor Therapy.Frontiers in immunology · 2022Review
- Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy.Nanoscale horizons · 2021Review
- Article
- Tracking adoptive T cell immunotherapy using magnetic particle imaging.Nanotheranostics · 2021Article
- Dual-modal magnetic resonance and photoacoustic tracking and outcome of transplanted tendon stem cells in the rat rotator cuff injury model.Scientific reports · 2020Article
- Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Non-invasive in vivo tracking of T-cells by magnetic resonance imaging (MRI) can lead to a better understanding of many pathophysiological situations, including AIDS, cancer, diabetes, graft rejection. However, an efficient MRI contrast agent and a reliable technique to track non-phagocytic T-cells are needed. We report a novel superparamagnetic nano-sized iron-oxide particle, IOPC-NH2 series particles, coated with polyethylene glycol (PEG), with high transverse relaxivity (250 s(-1) mM(-1)), thus useful for MRI studies. IOPC-NH2 particles are the first reported magnetic particles that can label rat and human T-cells with over 90% efficiency, without using transfection agents, HIV-1 transactivator peptide, or electroporation. IOPC-NH2 particles do not cause any measurable effects on T-cell properties. Infiltration of IOPC-NH2-labeled T-cells can be detected in a rat model of heart-lung transplantation by in vivo MRI. IOPC-NH2 is potentially valuable contrast agents for labeling a variety of cells for basic and clinical cellular MRI studies, e.g., cellular therapy. FROM THE CLINICAL EDITOR: In this study, a novel PEG coated superparamagnetic nano-sized iron-oxide particle was investigated as a T-cell labeling agent for MRI studies. The reported particles can label T-cells with over 90% efficiency, without using transfection agents, HIV-1 transactivator peptide, or electroporation, therefore may enable more convenient preclinical call labeling studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.